Jagsonpal Pharmaceuticals has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year ending March 31, 2026. The report details the company’s adherence to the National Guidelines on Responsible Business Conduct (NGRBC) across nine principles.

The disclosure covers governance structures, environmental impact, and social responsibility initiatives. Jagsonpal operates primarily in the marketing and distribution of pharmaceutical formulations, contributing 99.42% to its total turnover. The company reported a turnover of ₹2,872.25 million and a net worth of ₹2,942.09 million for the period.

Employee Welfare and Safety

The company employed 1,305 individuals as of March 31, 2026, comprising 1,297 permanent employees and 8 non-permanent staff. Women constitute 2% of the total workforce. The report notes that 100% of permanent male employees and 100% of female employees received health and life insurance coverage.

Safety incidents remain a focus area. The company recorded 16 road accidents involving employees in FY26, down from 25 in the previous year. Tragically, there was 1 fatality reported in FY26, consistent with the prior year’s figure. The company provided monetary support for hospitalization and post-discharge care through group insurance policies.

Environmental Impact and Waste Management

As a marketing and distribution entity without manufacturing facilities, Jagsonpal’s direct environmental footprint is limited to office operations and waste disposal. Total electricity consumption at the corporate office and warehouse stood at 1,07,869.3 kWh.

Waste management primarily involves the disposal of expired and damaged pharmaceutical goods. The company disposed of 39,122 kg of such waste via incineration in FY26, a decrease from 43,070 kg in FY25. All waste was handled by government-approved vendors to prevent re-entry into the market.

Governance and Stakeholder Engagement

The Board of Directors includes 33% women representation. No fines or penalties were paid to regulatory agencies during the year. The company resolved all 5 shareholder complaints and 7 customer complaints received in FY26, leaving zero pending cases.

What the Numbers Show

The reduction in waste disposal volume from 43,070 kg to 39,122 kg suggests improved inventory management or reduced product damage rates, aligning with operational efficiency goals despite the absence of manufacturing overheads.

Jagsonpal Pharmaceuticals Limited posted a strong turnaround in its first quarter of FY27, reporting a standalone net profit of ₹84.3 lakh for the period ended June 30, 2026. This marks a significant improvement from the net loss of ₹6.6 lakh recorded in the same quarter of FY25.

The company’s standalone revenue from operations expanded by 44% year-on-year to ₹2,000.6 lakh, driven by higher operational income. On a consolidated basis, total income from operations reached ₹20,291 lakh, up from ₹14,209 lakh in Q1FY25. Consolidated net profit after tax stood at ₹832 lakh, reversing the consolidated loss of ₹37 lakh reported in the prior year’s corresponding period.

Dividend Recommendation

At its meeting held on April 27, 2026, the Board of Directors recommended a final dividend of ₹4 per equity share (face value ₹2) for FY26. This payout includes a special one-time dividend of ₹1.5 per share. The record date for the dividend is fixed for September 4, 2026. Shareholders are advised to update their electronic bank mandates with depository participants to ensure timely receipt of dividends via Electronic Clearing Service.

What the Numbers Show

The financial data highlights a sharp operational recovery. While consolidated revenue grew by approximately 43% year-on-year, the shift from a consolidated net loss of ₹37 lakh to a profit of ₹832 lakh indicates improved cost efficiency or margin expansion alongside top-line growth. The inclusion of a special dividend component suggests management confidence in cash flows despite the modest absolute profit figures relative to revenue scale.

Corporate Governance and AGM

Jagsonpal Pharmaceuticals has scheduled its 47th Annual General Meeting (AGM) for September 18, 2026, at 3:30 pm IST. The meeting will be conducted through Video Conferencing/Other Audio Visual Means (VC/OAVM) as per MCA and SEBI guidelines. The Notice of AGM and the Annual Report for FY26 will be sent electronically to members with registered email addresses. Remote e-voting facilities are available for all shareholders.

Mr. Ayush Khandelwal has been appointed as the Scrutinizer for the e-voting process. Members holding shares in physical form without registered emails are requested to update their details using Form ISR-1 to receive future communications.